Global Market Study On Connective Tissue Growth Factor - Pipeline Review, H2 2017

"The Report Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

According to the recently published report Connective Tissue Growth Factor-Pipeline Review, H2 2017; Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)-Connective tissue growth factor (CTGF), also known as CCN2 is a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins. CTGF plays an important role in promoting fibroblast proliferation, migration, adhesion, and extracellular matrix formation, and its overproduction plays a major role in pathways that lead to fibrosis (TGF-beta-dependent). This includes fibrosis of major organs, fibroproliferative diseases, and scarring. CTGF also plays an important role in the extracellular matrix remodeling that occurs in normal physiological processes such as embryogenesis, implantation, and wound healing.

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/1361351

The report Connective Tissue Growth Factor-Pipeline Review, H2 2017 outlays comprehensive information on the Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 1, 5 and 1 respectively. Report covers products from therapy areas Gastrointestinal, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Ophthalmology, Cardiovascular and Musculoskeletal Disorders which include indications Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Diabetic Nephropathy, Duchenne Muscular Dystrophy, Hypertrophic Scars, Kidney Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Cancer, Scar, Systemic Sclerosis (Scleroderma), Acute Lung Injury, Age Related Macular Degeneration, Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Kidney Disease (Chronic Renal Failure), Cirrhosis, Cystic Fibrosis, Fatty Liver Disease, Fibrosis, Keloids, Liver Cancer, Metabolic Syndrome, Myocardial Fibrosis, Pancreatic Ductal Adenocarcinoma, Type 2 Diabetes and Wet (Neovascular / Exudative) Macular Degeneration.

View Report @ https://www.marketresearchreports.biz/reports/1361351/connective-tissue-growth-factor-ccn-family-member-2-or-hypertrophic-chondrocyte-specific-protein-24-or-insulin-like-growth-factor-binding-protein-8-or-igfbp8-or-ctgf-pipeline-review-h2-2017-market-research-reports

Scope

- The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)
- The report reviews Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.